XBiotech
XBIT
46 hedge funds and large institutions have $17.6M invested in XBiotech in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 10 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
0.39% more ownership
Funds ownership: 10.23% → 10.62% (+0.39%)
4% less funds holding
Funds holding: 48 → 46 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
31% less call options, than puts
Call options by funds: $689K | Put options by funds: $1M
70% less capital invested
Capital invested by funds: $59.3M → $17.6M (-$41.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.44M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$482K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$397K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$251K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$244K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.07M |
| 2 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
-$862K |
| 3 |
JP Morgan Chase
New York
|
-$410K |
| 4 |
FPF
FNY Partners Fund
New York
|
-$313K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$292K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FPF
51
FNY Partners Fund
New York
| – | -$313K | -19,014 | Closed |
|
|
SC
52
Sculptor Capital
New York
| – | -$145K | -8,800 | Closed |
|
53
SG Americas Securities
New York
| – | -$121K | -7,363 | Closed |
|
|
SO
54
STRS Ohio
Columbus,
Ohio
| – | -$65K | -4,000 | Closed |
|
55
Parallax Volatility Advisers
San Francisco,
California
| – | -$52K | -3,133 | Closed |
|
56
Creative Planning
Overland Park,
Kansas
| – | -$8K | -500 | Closed |
|
XBIT Hedge Fund Activity: Q2 2017 in Review
46 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2017, worth a combined $17.6M — down 70% from $59.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XBIT and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 17 added.
The largest buyer was BlackRock, adding an estimated $1.44M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.07M sold.
- 46 institutional investors held XBiotech (XBIT) as of Q2 2017, down from 48 in Q1 2017.
- Funds reported $17.6M of XBiotech stock for Q2 2017, down 70% quarter-over-quarter.
- 8 funds opened new XBiotech positions in Q2 2017 and 10 closed out, a net change of -2 holders.
- The largest XBiotech buyer in Q2 2017 was BlackRock, an estimated $1.44M added.
- The largest XBiotech seller in Q2 2017 was Balyasny Asset Management, an estimated $1.07M sold.
Based on aggregated 13F filings for Q2 2017.